Tailoring polymeric micelles for improved olaparib solubility and drug release

FHS
May 23, 2024
8:24 pm

Olaparib is a selective poly (ADP-ribose) polymerase inhibitor. However, its clinical application is hindered by low solubility and undesired pharmacokinetic profiles (e.g., relatively short circulation).

Sanofi reports rise in Q4 2024 net income to $833m

Sanofi has outlined plans to execute a share buyback programme of €5bn in 2025. Credit: ArDanMe/Shutterstock. Sanofi has announced an increase in net income from

January 31, 2025

Size of 340B market triples since 2018 and may double again, report says

The battle between pharma companies and hospitals over the federal drug discount program known as 340B is gaining steam as its size has tripled since 2018

May 14, 2024

Nearly 1 billion people likely to live with osteoarthritis by 2050, study estimates

A new study projects nearly 1 billion people will be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals

August 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.